BIOVAXYS TECHNOLOGY CORP. (F:5LB) — Market Cap & Net Worth
Market Cap & Net Worth: BIOVAXYS TECHNOLOGY CORP. (5LB)
BIOVAXYS TECHNOLOGY CORP. (F:5LB) has a market capitalization of $3.75 Million (€3.20 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #28878 globally and #2513 in its home market, demonstrating a 1320.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIOVAXYS TECHNOLOGY CORP.'s stock price €0.15 by its total outstanding shares 29342500 (29.34 Million).
BIOVAXYS TECHNOLOGY CORP. Market Cap History: 2020 to 2025
BIOVAXYS TECHNOLOGY CORP.'s market capitalization history from 2020 to 2025. Data shows change from $4.53 Million to $5.11 Million (-2.47% CAGR).
BIOVAXYS TECHNOLOGY CORP. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIOVAXYS TECHNOLOGY CORP.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 5LB by Market Capitalization
Companies near BIOVAXYS TECHNOLOGY CORP. in the global market cap rankings as of May 5, 2026.
Key companies related to BIOVAXYS TECHNOLOGY CORP. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
BIOVAXYS TECHNOLOGY CORP. Historical Marketcap From 2020 to 2025
Between 2020 and today, BIOVAXYS TECHNOLOGY CORP.'s market cap moved from $4.53 Million to $ 5.11 Million, with a yearly change of -2.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €5.11 Million | +345.07% |
| 2024 | €1.15 Million | +90.34% |
| 2023 | €603.76K | -76.78% |
| 2022 | €2.60 Million | -44.26% |
| 2021 | €4.67 Million | +3.03% |
| 2020 | €4.53 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of BIOVAXYS TECHNOLOGY CORP. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.75 Million USD |
| MoneyControl | $3.75 Million USD |
| MarketWatch | $3.75 Million USD |
| marketcap.company | $3.75 Million USD |
| Reuters | $3.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BIOVAXYS TECHNOLOGY CORP.
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S)… Read more